Skip to main content

$0.125 (0.00%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
17 May 2025 at 7:43am
Register to track EMD and receive email alerts.

Emyria to Develop Psilocybin Therapy Care Model

StockBot

416,823 posts

EMD released this announcement to the ASX on 18 April 2023, 8:15. The announcement is marked as price sensitive, and is 4 page(s) in length and 1.16MB in size.

You can view all announcements from EMD and see how they appear on a price chart on the announcements page.

At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).

Other Recent Announcements from EMD
Trading Halt 29 June 2023, 9:33
Emyria Receives Ethics Approval for MDMA-assisted Therapy 8 June 2023, 9:10
Section 708A(5)(e) Notice 10 May 2023, 18:37
Emyria to Develop Psilocybin Therapy Care Model 18 April 2023, 8:15
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5 4 April 2023, 8:53
Strong Recruitment for EMD-RX5 Phase 3 Trial 23 March 2023, 8:16
Emyria Grows MDMA Asset for Neuro & Mental Health Therapy 20 March 2023, 8:10
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track EMD and receive email alerts.